BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs, a clinical-stage biotechnology company, announced it will participate in the Jefferies Global Healthcare Conference (June 3-4, 2026) and Goldman Sachs Global Healthcare Conference (June 8-10, 2026). Company executives will present and hold one-on-one meetings at both events. BioAge is developing BGE-102, an NLRP3 inhibitor for cardiometabolic diseases, with Phase 2 cardiovascular data expected by end of 2026.

05/22/2026, 9:00 AM • GlobeNewswire

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.

05/20/2026, 9:50 AM • Benzinga

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Labs announced positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing potential best-in-class reductions in hsCRP (high-sensitivity C-reactive protein) of ≥85% at both 60 mg and 120 mg once-daily doses in participants with obesity and elevated inflammation. The drug was well tolerated across all dose levels. The company plans to initiate a Phase 2 cardiovascular risk proof-of-concept trial in mid-2026 with results expected by year-end, and a Phase 1b/2a trial in diabetic macular edema also planned for mid-2026.

04/21/2026, 7:00 AM • GlobeNewswire

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 5.9 million shares at $19.50 per share, raising approximately $115 million in gross proceeds. The company plans to use the funds for research, development, and manufacturing of its product candidates, including the lead candidate BGE-102 (an NLRP3 inhibitor), APJ agonist programs, and general corporate purposes. The offering is expected to close on January 23, 2026.

01/21/2026, 10:30 PM • GlobeNewswire

BioAge Announces Proposed Public Offering

BioAge Labs (NASDAQ: BIOA), a clinical-stage biopharmaceutical company focused on metabolic diseases and aging biology, announced a proposed underwritten public offering of up to $75 million in common stock, with an additional $11.25 million option for underwriters. The company plans to use proceeds for research, development, and manufacturing of product candidates including BGE-102, NLRP3, and APJ programs. Goldman Sachs, Piper Sandler, and Citigroup are acting as joint book-running managers.

01/20/2026, 4:01 PM • Benzinga

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BioAge Labs announced expansion of its BGE-102 NLRP3 inhibitor development program into ophthalmology, planning to initiate a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) patients in mid-2026. The oral therapy has demonstrated favorable tolerability and robust reductions in inflammatory biomarkers in ongoing Phase 1 trials, with potential to reduce treatment burden compared to current intravitreal injection therapies. Results from the DME trial are anticipated in mid-2027, running parallel to a cardiovascular risk Phase 2a trial with results expected in 2H26.

01/20/2026, 9:00 AM • GlobeNewswire

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole

The article discusses why BioAge Labs is a risky investment, highlighting its early-stage clinical candidate BGE-102 in weight management and the competitive landscape of obesity treatments.

12/13/2025, 10:15 AM • The Motley Fool

Top 3 Biotech Stocks Capitalizing on the AI Revolution

Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.

11/18/2025, 1:02 PM • Investing

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

BioAge Labs will present at the Jefferies Global Healthcare Conference in London, with CEO Kristen Fortney and CFO Dov Goldstein participating in a fireside chat and one-on-one meetings, discussing their clinical-stage biotechnology work on metabolic disease therapies.

11/07/2025, 9:00 AM • GlobeNewswire

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?

BioAge Labs' stock jumped 46.6% after a Citigroup analyst upgraded its rating to buy, citing potential for its experimental weight management drug BGE-102 that targets brain inflammation and appetite regulation.

10/26/2025, 6:33 PM • The Motley Fool

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs initiated a Phase 1 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor targeting obesity treatment, with potential to address neuroinflammation and complement existing therapies like GLP-1 agonists.

08/15/2025, 9:00 AM • GlobeNewswire

BioAge Labs (BIOA) Q2 Revenue Hits $2.4M

BioAge Labs reported Q2 2025 earnings with first collaboration revenue of $2.41 million, increased R&D expenses, and continued development of obesity and metabolic disease treatments, including BGE-102 and APJ agonist programs.

08/06/2025, 11:14 PM • The Motley Fool